Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients ...
Knowing if and how rapidly an emerging pathogen will spread through a population enables public health officials to make well-informed decisions to protect the public. ...
Switching patient solutions providers, also known as hub providers, is a big decision for any pharmaceutical manufacturer or life sciences organization. The transition can be ...
President Trump’s big agreement with a new US drugmaker to supply drugs for COVID-19 has been overshadowed by his admission he is taking hydroxychloroquine as ...
It would be hard to miss the current interest in finding effective treatment for COVID-19. In this regard, the combination of hydroxychloroquine (HCQ) with azithromycin ...
The 11th edition of the Biopharma Cold Chain Sourcebook has been published by Pharmaceutical Commerce. The annual edition forecasts an overall market for cold chain ...
NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people with HER2-positive early breast cancer who are at ...
Quickly communicating pertinent clinical information, such as research regarding patient treatments, is critical during public health crises like the ongoing novel coronavirus disease 2019 (COVID-19) ...
Automation exists in most hospital pharmacies, but there are crucial gaps and onerous workarounds. “Medication intelligence” would be the preferred approach, according to an annual ...
Shares in US pharma Vertex were up sharply in premarket trading after its newly-launched cystic fibrosis triple therapy attained blockbuster status almost overnight, leading to a surprise upgrade to ...